ES2397193R1 - Usos de la prueba de reduccion del nitro-azul de tetrazolio - Google Patents

Usos de la prueba de reduccion del nitro-azul de tetrazolio

Info

Publication number
ES2397193R1
ES2397193R1 ES201190062A ES201190062A ES2397193R1 ES 2397193 R1 ES2397193 R1 ES 2397193R1 ES 201190062 A ES201190062 A ES 201190062A ES 201190062 A ES201190062 A ES 201190062A ES 2397193 R1 ES2397193 R1 ES 2397193R1
Authority
ES
Spain
Prior art keywords
reduction test
nitro
blue reduction
titrazol
blue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201190062A
Other languages
English (en)
Other versions
ES2397193A2 (es
ES2397193B1 (es
Inventor
Beguer Josep M Homedes
Ochoa Pablo Gomez
Elias David Sabate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecuphar Nv
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2397193A2 publication Critical patent/ES2397193A2/es
Publication of ES2397193R1 publication Critical patent/ES2397193R1/es
Application granted granted Critical
Publication of ES2397193B1 publication Critical patent/ES2397193B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Usos de la prueba de reducción del nitro-azul de tetrazolio. La invención se refiere a los usos de la prueba de reducción del nitro-azul de tetrazolio para el seguimiento clínico de la leishmaniosis canina. La invención también se refiere al uso de la prueba de reducción del nitro-azul de tetrazolio para la determinación del porcentaje de monocitos y neutrófilos activados y para la determinación y monitorización de la respuesta inmune en perros sanos.
ES201190062A 2009-03-31 2010-03-30 Usos de la prueba de reducción del nitro-azul de tetrazolio Expired - Fee Related ES2397193B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382040 2009-03-31
EP09382040A EP2241317A1 (en) 2009-03-31 2009-03-31 Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response
PCT/EP2010/054177 WO2010112497A1 (en) 2009-03-31 2010-03-30 Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response

Publications (3)

Publication Number Publication Date
ES2397193A2 ES2397193A2 (es) 2013-03-05
ES2397193R1 true ES2397193R1 (es) 2013-03-25
ES2397193B1 ES2397193B1 (es) 2013-11-26

Family

ID=40801995

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10711405.0T Active ES2559762T3 (es) 2009-03-31 2010-03-30 Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevención de una enfermedad asociada a una alteración de la respuesta inmunitaria
ES201190062A Expired - Fee Related ES2397193B1 (es) 2009-03-31 2010-03-30 Usos de la prueba de reducción del nitro-azul de tetrazolio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10711405.0T Active ES2559762T3 (es) 2009-03-31 2010-03-30 Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevención de una enfermedad asociada a una alteración de la respuesta inmunitaria

Country Status (9)

Country Link
US (1) US8802691B2 (es)
EP (2) EP2241317A1 (es)
AR (1) AR076016A1 (es)
DK (1) DK2413934T3 (es)
ES (2) ES2559762T3 (es)
HU (1) HUE027348T2 (es)
PL (1) PL2413934T3 (es)
PT (1) PT2413934E (es)
WO (1) WO2010112497A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3949965A1 (en) * 2020-08-07 2022-02-09 Consejo Superior de Investigaciones Cientificas Domperidone for use as antiviral agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372818A (en) * 1993-02-01 1994-12-13 Clemson University Method of treating fescue toxicosis with domperidone
US6224895B1 (en) 1996-12-18 2001-05-01 Clemson University Method for promoting ovulation, parturition, and lactation in mammals
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
ES2246142B1 (es) 2004-06-03 2007-03-16 Consejo Sup. Investig. Cientificas Nueva composicion terapeutica inmunomoduladora.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
01/01/1977, SCHILIRO G et al. Granulocyte function in visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 01/01/1977 VOL: 71 No: 5 Pags: 439 - 440 ISSN 0035-9203 Doi: doi:10.1016/0035-9203(77)90048-7, columna 1, resumen, introducción, columna 2 discusión. *
30/11/1985, REMALEY A T et al. Leishmania donovani: Surface membrane acid phosphatase blocksneutrophil oxidative metabolite production. Experimental Parasitology 00/12/1985 VOL: 60 No: 3 Pags: 331 - 341 ISSN 0014-4894página 332, columna 2, 5º párrafo. *
31/03/1985, DEGORSKI A et al. Serum lysozyme activity in relation to the nitroblue tetrazoliumreduction test in newborn calves and cows.. Zentralblatt Veter. rmedizin. VOL: 32 No: 4 Pags: 241 - 248 ISSN 0514-7158 (Print) Doi: pubmed:3927615, página 247, resumen. *
31/07/1991, LECHOWSKI R et al. Serum lysozyme activity and nitroblue tetrazolium reduction test indogs with diabetes mellitus.. Zentralblatt. Veter. medizin. VOL: 38 No: 7 Pags: 530 - 533 ISSN 0514-7158 (Print) Doi: pubmed:1950244, página 530, resumen, página 531, tabla 1. *

Also Published As

Publication number Publication date
EP2413934A1 (en) 2012-02-08
EP2413934B1 (en) 2015-10-21
PL2413934T3 (pl) 2016-05-31
ES2397193A2 (es) 2013-03-05
ES2559762T3 (es) 2016-02-15
AR076016A1 (es) 2011-05-11
DK2413934T3 (en) 2016-01-25
HUE027348T2 (en) 2016-10-28
US8802691B2 (en) 2014-08-12
PT2413934E (pt) 2016-01-25
ES2397193B1 (es) 2013-11-26
EP2241317A1 (en) 2010-10-20
US20120065167A1 (en) 2012-03-15
WO2010112497A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
IL264770B (en) Diagnostic assays and kits for detection of folate receptor 1
CO6801640A2 (es) Ensayos interrogatorios basados en células y usos de los mismos
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
MX2019005251A (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
CO6821931A2 (es) Inhibidores selectivos de la glicosidasa y usos de los mismos
EP4154815C0 (en) SAFETY BLOOD COLLECTION KIT WITH INDICATOR
PT2857132T (pt) Pastilha de corte de dupla face
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
MX2015012733A (es) Metodos y composiciones para evaluar el estado renal usando adn libre de celulas de la orina.
UY33109A (es) Nuevos antagonistas del receptor CCR2 y usos de los mismos
BRPI1011321A2 (pt) dispositivo de monitoramento de analito de métodos de uso
BR112012002351A2 (pt) ferramenta de intervenção e diagnóstico de acidente vascular cerebral para despacho de emergência
EP2815458A4 (en) MEDICAL APPLICATIONS OF A DOUBLE HELLIX LEITER
BR112013016161A2 (pt) módulo de monitoração segura para medição de utilidade.
CL2015000097A1 (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos.
CL2015002030A1 (es) Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
PL2453988T3 (pl) Sposób korzystania z urządzenia asekuracyjnego
BRPI0921186A2 (pt) purificação de alcoóis antes do seu uso na presença de um catalisador de ácido
MX383670B (es) Nuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos.
BR112014030591A2 (pt) "método para a preparação de uma maionese livre de edta, maionese livre de edta e uso do suco reduzido de uva como como substituto de edta"
BR112012001765A2 (pt) dispositivo de talabarte de segurança e sistema pessoal de resposta emergencial
CO7350653A2 (es) Retinoides y uso de los mismos
GB201222925D0 (en) Body fluid guidingcapillary structure for self-contained test unit
BRPI1014373A2 (pt) aparelho para rapidamente verificar tolerâncias de componentes de precisão

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2397193

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20131126

PC2A Transfer of patent

Owner name: ECUPHAR N.V

Effective date: 20160118

FD2A Announcement of lapse in spain

Effective date: 20220629